NCT06519656

Efficacy of Mazdutide for Treating PCOS

A Clinical Efficacy Study of Mazdutide in the Treatment of Polycystic Ovary Syndrome

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Shanghai Zhongshan Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn the efficacy of Mazdutide in treating obese female adults diagnosed with polycystic ovary syndrome (PCOS). The main question it aims to answer is: Does Mazdutide lower the free androgen index (FAI) in obese female adults with PCOS? Participants will take Mazdutide once every week for 24 weeks and visit the clinic once every 4 weeks for checkups and tests.

Conditions

• Polycystic Ovary Syndrome

Interventions

Type	Name	Description
DRUG	Mazdutide	In the initial 4 weeks, the subjects are given Mazdutide 2mg once weekly. If well tolerated, the dosage is increased to 4mg once weekly for another 4 weeks. If still well tolerated, the dosage is further increased to 6mg once weekly and maintained for the ensuing 16 weeks.

Timeline

• Start date: 2024-10-21
• Primary completion: 2025-12-31
• Completion: 2026-06-30
• First posted: 2024-07-25
• Last updated: 2024-10-24

Locations

1 site across 1 country: China